<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="111094">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02094365</url>
  </required_header>
  <id_info>
    <org_study_id>ALS-8176-502</org_study_id>
    <nct_id>NCT02094365</nct_id>
  </id_info>
  <brief_title>A Phase 2a Study to Evaluate ALS-008176 in the Virus Challenge Model</brief_title>
  <official_title>A Randomised, Phase 2a, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Pharmacokinetics and Antiviral Activity of Multiple Doses of Orally Administered ALS-008176 Against Respiratory Syncytial Virus Infection in the Virus Challenge Model</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alios Biopharma Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alios Biopharma Inc.</source>
  <oversight_info>
    <authority>United Kingdom: Medicines and Healthcare Products Regulatory Agency</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to compare the antiviral effect of ALS-008176 compared to a placebo
      control in the respiratory syncytial virus challenge model.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2014</start_date>
  <primary_completion_date type="Anticipated">August 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Change in viral load measurements.</measure>
    <time_frame>Baseline  to day 12</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">66</enrollment>
  <condition>Respiratory Syncytial Virus Infections</condition>
  <arm_group>
    <arm_group_label>ALS-008176</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ALS-008176 drug substance for oral suspension</description>
  </arm_group>
  <arm_group>
    <arm_group_label>vehicle alone</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Vehicle alone</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ALS-008176</intervention_name>
    <arm_group_label>ALS-008176</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vehicle</intervention_name>
    <arm_group_label>vehicle alone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18 to 45 years, inclusive.

          -  In good health with no history of major medical conditions

          -  A total body weight â‰¥ 50 kg and a body mass index (BMI) of &gt; 18kg/m2.

        Exclusion Criteria:

          -  Acute or chronic medical illness

          -  Positive for Human Immunodeficiency Virus, Hepatitis B or C

          -  Nose or nasopharynx abnormalities

          -  Abnormal lung function
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hosnieh Fathi, MD, MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Retroscreen Virology Ltd.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Retroscreen Virology Ltd</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Temi Giwa, MD, MSci</last_name>
      <phone>787 508 4287</phone>
    </contact>
    <investigator>
      <last_name>Hosnieh Fathi, MD, MSc</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 20, 2014</lastchanged_date>
  <firstreceived_date>March 20, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Respiratory Syncytial Virus Infections</mesh_term>
    <mesh_term>Virus Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
